Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 185

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 185
---
 in which any of our directors, executive officers or holders of more than 5% of our outstanding capital stock, or any immediate family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest.

On December 31, 2024, the Company’s Chief
Operating Officer, exercised 2,800,000 stock options into 2,800,000 common stock at an exercise price of $0.001 per share.

On December 31, 2024, the Company’s
Board of Directors approved a grant to the Chief Technology Officer of LipoVation, the Company’s subsidiary, 740,000 stock options
at an exercise price of $0.30 per share, of which as of the date of this prospectus 740,000 options were fully vested.

On February 9, 2024, the Company’s Board
of Directors approved a grant to the Company’s then Chief Executive officer of 3,800,000 stock options at an exercise price of $0.001
per share 1,900,000 options were fully vested upon grant and the remaining 1,900,000 options are scheduled to vest on a quarterly basis
over two years in equal quarterly instalments of 237,500 options, beginning with the quarter ended March 31, 2024. The options are exercisable
within eight years from the grant date.

On February 9, 2024, the Board approved a grant
to the Chairman of the Board of 160,000 stock options at an exercise price of $0.40 per share, of which 80,000 options were fully vested
upon grant and the remaining 80,000 options are scheduled to vest on a quarterly basis over 2 years in equal quarterly instalments of
10,000 options, beginning with the quarter ended March 31, 2024. The options are exercisable within eight years from the grant date.

On February 9, 2024, the Board agreed to extend
the exercise period of options for 690,000 shares previously granted in 2021 to a director then serving on the Board and a service provider
through the original date of grant (i.e., September 30, 2031). The extension was granted in connection with the service provider’s
resignation from service to the Company.

<div align='center'>114

DESCRIPTION OF SECURITIES</div>

Prior to the Reincorpor